Add a bookmark to get started

24 May 20231 minute read

Global M&A Intelligence Report 2023 – Life Sciences Supplement

An analysis of the trends, challenges and opportunities in the global life sciences M&A market

This report provides an insight into life sciences M&A deal activity in 2022 and supplements our 2023 global M&A intelligence report, which is now in its ninth edition.

The life sciences sector is broad and captures a number of sub-sectors, including pharmaceutical, medical devices and biotech.

The report looks at a selection of our international corporate life sciences transactions to identify trends and developments, which can provide insightful intelligence for those operating in the sector and considering M&A activity, both domestically or internationally.

The report focuses on five key themes:

  • Due Diligence (DD)
  • Warranty and Indemnity (W&I) insurance
  • Transaction structures 
  • Trade v Private Equity 
  • US v Rest of the World (RoW)  

“Buyers and investors must pay close attention in conducting adequate regulatory due diligence, when evaluating targets in rapidly evolving environments.”

Marco de Morpurgo, Global Co-Chair and EU Regulatory Lead – Life Sciences

Please note, requests will be reviewed and approved at the discretion of DLA Piper. We cannot guarantee you will receive the report after submitting a request. Alternatively, please get in touch with your usual DLA Piper contact to request a copy.